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Serogroup W135 ST-2881 meningococci caused a
cluster of meningitis cases in Niger in 2003. Of 80 healthy
persons in the patients’ villages, 28 (35%) carried meningo-
cocci; 20 of 21 W135 carrier strains were ST-2881. Ten
months later, 5 former carriers were still carriers of W135
ST-2881 strains. The serum bactericidal antibody activity
changed according to carrier status.
N
iger is located in the African “meningitis belt” (1).
Until recently, meningococcal meningitis epidemics
in Niger were caused primarily by Neisseria meningitidis
serogroup A. Since the first epidemic in Africa, caused by
N. meningitidis serogroup W135 (NmW135) in Burkina
Faso in 2002, Niger has enhanced its microbiologic sur-
veillance. Few laboratories perform etiologic diagnoses,
but health staff can send frozen cerebrospinal fluid (CSF)
specimens to the national reference laboratory, Centre de
Recherche Médicale et Sanitaire (CERMES), for microbi-
ologic determination by PCR (2,3).
In March and April 2003, the district of Illela reported
154 suspected cases of meningitis. The epidemic threshold
of 10 cases/100,000 inhabitants/week was crossed at week
12. The incidence decreased by week 14, with no vaccina-
tion campaign (Figure).
Etiologic diagnosis was not made immediately, but 15
frozen and stored CSF specimens were retrieved in May.
Among the 11 specimens with positive PCR results for N.
meningitidis, 5 were NmW135 and 6 were NmA. All cases
caused by NmW135 were reported by the Illela health cen-
ter (14°27′N, 05°14′E) and were in patients living in 5 sur-
rounding villages.
To understand the limited size of this cluster of
NmW135 cases in a population never vaccinated against
this serogroup, we surveyed the prevalence and duration of
meningococcal carriage among inhabitants of patients’vil-
lages. We also assessed the seroprevalence and immuno-
logic response induced by carriage.
The Study
Carriage studies carried out by CERMES were
approved by the national ethics committee of Niger in
February 2003. We conducted our first investigation in
May 2003 in 4 of the 5 villages where the meningitis
patients were living. In each village, we enrolled 20 con-
senting persons, 10 who lived in a patient’s household,
considered close contacts, and 10 who lived in a remote
part of the village and had limited contact with patients
(controls). The mean ages were 12.9 years (range 2–65
years) in the close contacts group and 12.1 years (range
6–25 years) in the other group.
Oropharyngeal swab specimens were immediately plat-
ed on chocolate agar. Plates were incubated at 37°C in a
candle jar. From each culture that showed macroscopic
evidence of Neisseria, 3 colonies were subcultured onto
chocolate agar plates. Gram-negative oxidase-positive and
catalase-positive cocci were then inoculated onto cystine
trypticase agar. N. meningitidis serogrouping was per-
formed by using specific antisera (Difco Laboratories,
Detroit, MI, USA).
We collected a second oropharyngeal swab specimen
from the same persons in February 2004. The swabs were
processed as before. Meningococcal strains were sent to
the WHO Collaborating Centre for Meningococci
(Marseille, France) for serogroup confirmation, serotyp-
ing, multilocus sequence typing (MLST) (4), and pulsed-
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Figure. Weekly reports of suspected cases of meningitis, District of
Illela, 2003. field gel electrophoresis (PFGE) (5). When 2 or 3 strains
of the same serogroup were obtained from the 3 subcul-
tured colonies, only 1 was sent for further analysis. An
unpublished study by the meningococcus unit in Marseille
showed that meningococci having the same PFGE finger-
print patterns belonged to the same sequence type (ST).
However, not all meningococci belonging to the same ST
had the same fingerprint pattern. Here, we attributed the
same ST to all the isolates having the same fingerprint pat-
tern, and all the isolates differing by >1 band were
sequenced.
Serum samples were collected at the same time as the
first and second throat specimens. We assessed the
immunologic response to NmW135 by using the serum
bactericidal antibody (SBA) assay, carried out according to
the method of Maslanka et al. (6), and the standard operat-
ing procedure of the Vaccine Evaluation Department of the
Manchester Medical Microbiology Partnership
(VED/MMMP). We used the NmW135 ST-184 strain M01
240070 (W135:NT:P1.18–1,3) as a reference strain but
also used a W135 (W135:NT:P1.5,2) ST-2881 local strain
for comparison. Baby rabbit serum was used as a comple-
ment source. An SBAassay titer >8 for NmW135 was con-
sidered to reflect a protective immunity to this serogroup,
according to the correlation established from NmC SBA
(7). External quality control was conducted by
VED/MMMP.
In May 2003, 28 (35%) of 80 villagers carried
meningococci: 21 (26.3%) carried NmW135 strains, 2
(2.5%) carried NmY strains, and 5 (6.3%) had non-
groupable strains. Carriage of NmW135 strains was not
related to age or sex but was significantly more frequent
among members of patients’ households (40% vs 12.5%).
Of the 28 recovered strains, 27 had an nontypable
(NT):P1.5,2 phenotype irrespective of the serogroup. All
28 isolates were studied by using PFGE, and 10 were char-
acterized by MLST. One of the 28 strains recovered in
May 2003 was W135:2a:P1.2, ST-11; these characters
were the same as those of the strain that was responsible
for the epidemic in Burkina Faso in 2002. On the basis of
MLST results for 9 strains that had the same PFGE pattern
as all other isolates, 27 strains were attributed to ST-2881.
Before 2003, ST-2881 strains had never been associated
with invasive meningococcal disease (8,9).
We repeated the survey in February 2004. No new case
of meningitis had occurred meanwhile. We could follow
up 70 of the original participants. One (1.4%) carried
NmY, 1 had a strain that could not be grouped, and 7 (10%)
carried NmW135. Of these 7, five were already NmW135
carriers in May 2003, whereas another had carried a non-
groupable strain. All 9 strains were ST-2881. Four of the 5
pairs of NmW135 strains had the same PFGE pattern in
May 2003 and in February 2004, while the fifth pair dif-
fered in only 1 band. These 5 persons most likely carried
these strains throughout the 10 months. Lastly, 2 addition-
al persons (2.8%), who were not carriers in 2003, carried
NmX, ST-181, in 2004. 
MLST was successful in CSF specimens from 4 of the
5 patients. It showed that NmW135, which had caused the
cases, also belonged to ST-2881.
The proportion of villagers with SBAassay titer >8 was
not significantly different between close contacts and con-
trols. The proportion of persons presumably protected
against the local NmW135 ST-2881 strain increased from
25.8% to 41.9% (p = 0.03) within 10 months. Conversely,
the proportion of persons with SBA assay titer >8 for the
reference NmW135 ST-184 strain did not increase signifi-
cantly (33.8% to 36.9%, p = 0.8). For persons with SBA
assay titer <8 for the local strain in 2003, the proportion
protected in February 2004 was significantly higher (p =
0.04) among those who were carriers in May 2003 (Table).
For the reference strain, the difference was not significant
between carriers and noncarriers (36.4% vs 15.6%, p =
0.2). Of the 6 NmW135 carriers in May 2003 who had an
SBA assay titer <8 in 2003 and 2004 (Table), 2 were still
NmW135 carriers in 2004.
Conclusions
Strains expressing the same polysaccharide (W135)
gave slightly different SBA assay results. Antibodies
against subcapsular antigens, likely PorA, may explain this
finding. Studies have shown that carriage of >1 meningo-
coccus genotype is rare. Therefore, the long-term carriage
of NmW135 ST-2881 strains may have hampered colo-
nization by another genotype, such as the hypervirulent
NmW135 ST-11 strains. A recent study of religious pil-
grims and their family contacts confirmed that NmW135
carriage could persist for several months (10). In May
2003, most carriers carried the same genotype, as observed
during epidemics in which a single genotype usually
emerges.
The carriage of isolates having the same subtype, ST,
and fingerprint patterns but different polysaccharides,
W135 and Y, suggests that capsule switching from W135
to Y is easy. This possibility is worrisome because the
trivalent vaccine used in Africa to control NmW135 out-
breaks does not contain the Yvalence. NmW135 in menin-
gitis patients in Niger was first reported in 1981 (11). The
NmW135 clinical isolate of the ET-37/ST-11 clonal com-
plex recovered in 2001 was the first to be typed (12). Since
2002, enhanced surveillance of meningitis showed the
wide geographic spread of NmW135 in Niger (13). In
2003, ST-2881 represented >50% of NmW135 strains
from patients in Niamey (8). This ST, which had never pre-
viously been associated with sporadic meningitis, has also
been identified in Benin and Nigeria (9). The origin and
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of microbiologic surveillance outside Niamey before 2002.
We report a cluster of cases that did not spread, despite the
absence of a vaccination campaign and a high prevalence
of long-lasting carriage. Until now, most strains with a
genotype closely related to ST-2881 were carrier strains
(8). ST-2881, which has a possibly lower virulence than
the ST-11 strains, should be investigated in mice (14).
Extensive circulation and asymptomatic carriage of ST-
2881 strains in Niger may have prevented an epidemic by
the virulent clonal complex ST-11. Carriage was signifi-
cantly associated with development of a presumably pro-
tective immunity to the local ST-2881 strain. The
association was not statistically significant for the refer-
ence ST-184 strain, but the limited sample size was not
suitable for a high statistical power. Would the immunity
induced by carrier NmW135 ST-2881 strains be sufficient
to prevent an epidemic caused by the ST-11? Did the long-
term carriage of a less virulent strain hamper colonization
by a hypervirulent one? Addressing these 2 questions
might contribute to understanding why the Burkina Faso
outbreak did not hit Niger. This study highlights the impor-
tance of tracing NmW135 strains by MLST to monitor
changes in the epidemiology of NmW135 in Africa.
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